The solution-phase complex assay for toxins A, B, and E from Clostridium botulinum (Elcatech, Inc., Winston-Salem, N.C.) was modified to measure antibody. The addition of unlabeled polyclonal antibodies to a mixture consisting of toxin with chicken antibody and RW-XA-labeled horse antibody reduces the sensitivity of detection of neurotoxin. This reduction in sensitivity can be used as a measure of the specific antibody titer.
The measurement of specific antibodies to the neurotoxins of Clostridium botulinum is typically accomplished by an in vivo assay in which lethal toxin is neutralized prior to injection into a mouse (3, 5) . It has been noted that the enzyme-linked immunosorbent assay (ELISA) alternative with plates coated with neurotoxin and labeled second antibodies does not provide results comparable to those obtained by the bioassay (4) .
We have recently introduced several amplified immunoassay protocols for the measurement of neurotoxins A, B, and E (1, 2) . In one variant protocol, chicken antibodies and RVV-XA- A total of 2 ng of neurotoxin per ml was mixed with the indicated concentration of horse IgG isolated from the serum of a horse immunized with neurotoxin B. The mixture was then added to the tube of the ELISA-ELCA kit containing chicken antibody and RVV-XA-labeled horse antibody, and the tube was incubated for 60 min at 370C. The mixture was then serially diluted, as indicated in the figure, onto a plate coated with goat anti-chicken IgY, incubated for 60 min at 37°C, washed, and assayed by ELISA-ELCA. J. CLIN. MICROBIOL. labeled horse antibodies are incubated with neurotoxin, and the complex that is formed is bound to a capture plate consisting of antibody to chicken immunoglobulin G (IgG) (1) . Assays that use this protocol have recently been developed in kit form for the measurement of neurotoxins A, B, and E (Elcatech, Inc., Winston-Salem, N.C.).
We wished to explore whether these kits could be used to measure polyclonal human and horse antibodies to toxins. We reasoned that if unlabeled human or horse antibody specific to neurotoxin was added to the mixture of chicken antibody and RVV-XA-labeled horse antibody, the added unlabeled antibody would compete with both the chicken antibody and the RVV-XA-labeled antibody and cause a reduction in the amount of labeled complex which would bind to the capture plate (goat anti-chicken IgY). To test this, we used Elcatech kits to measure neurotoxins A, B, and E, to which we added 10 mg of immunoglobulin fraction from nonimmunized horses per ml. Specific antibodies from immunized horses and immunized human volunteers were tested by using this modified kit. The technology described here is protected under U.S. patent 4,668,621 and foreign analogs that have been issued or that are pending. The procedure described above was found to be a usable approach to measure specific antibody. Figure 1 shows a microtiter plate in which an assay for 2 ng of neurotoxin B per ml was inhibited by the presence of unlabeled horse antibody specific for neurotoxin B. This is seen by the fact that the complex gave a detectable signal at a lower dilution in the presence of the specific horse antibody. The level of inhibition was related to the amount of antibody added. a Samples from three subjects were used and were designated I, II, and III. A total of 1.0 ng of the appropriate neurotoxin per ml was added.
which the complex of neurotoxins A, B, and E was detectable and the amount of specific unlabeled horse antibody which was present. In this case, the antiserum to toxin B had the highest titer (less IgG was needed to inhibit complex formation) and antibody to toxin A had the lowest titer. Table 1 shows that the neutralization assay was specific; antibody to toxin A was not able to inhibit the formation of complexes involving toxins B and E, antibody to toxin B did not inhibit assays for toxin A or E, and antibody to toxin E did not inhibit assays for toxins A or B.
For human antisera and antiplasma, which were obtained from individual volunteers who were immunized with pentavalent toxoid (ABCDE) from the Centers for Disease Control and Prevention, we obtained the results shown in Table 2 . All were effective in inhibiting the amount of complex formed, in comparison with buffer controls and a nonimmune plasma pool.
The results presented above suggest that the same assay protocol which we developed to measure neurotoxin can be used to measure specific antibodies. The concentration of neurotoxin used for the assay can be varied, enabling one to test neutralization in both the mouse bioassay and the ELISAenzyme-linked coagulation assay (ELCA) alternative at a single toxin concentration. The low concentrations which can be used in this assay (50 pg/ml to 2 ng/ml) are much lower than those required for standard ELISA protocols, which use coating neurotoxin concentrations as high as 1 ,ug/ml. Neutralization assays are typically performed with 100 pg or less of neurotoxin per ml (3, 5) .
We have noted before (1) that a significant artifact which could complicate the use of the ELISA-ELCA system for measurement of neurotoxin in extracts of highly contaminated foods or fecal samples would be the binding of RVV-XAlabeled antibody to the microtiter plate via proteins A or G or lectins (for example). We attempted to eliminate this artifact by adding relatively high concentrations of non-immune horse IgG (10 mg/ml) to the assay kit. The observations made here suggest a further test for confirmation of the specificity of the ELISA-ELCA with these highly contaminated samples, that is, the addition of neutralizing horse antibody to the assay at a concentration of IgG (0.01 to 1.0 mg/ml) that will not eliminate any nonspecific trace binding but that will saturate the neurotoxin with unlabeled antibody. This approach is formally analogous to the use of toxin neutralization by specific antiserum as a confirmatory test in mouse bioassays. 
